Celiac and IBD: unlocking how genes influence disease with DNA methylation
Official title: Celiac and inflammatory bowel diseases: functional post-GWAS approach
Funded at Hackensack University Medical Center · NIH-11395373 · Data updated 2026-11-12
A research project aims to use genetic and epigenetic clues to better understand why celiac disease and inflammatory bowel disease affect people differently and how they respond to treatment.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Hackensack University Medical Center NIH-funded |
| Lab location | 1 site (Hackensack, United States) |
| Project start | August 19, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $889,388 |
| NIH project number | 5R01AI173261-03 |
| Project ID | NIH-11395373 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with celiac disease or inflammatory bowel disease, and potentially those at risk who could benefit from improved risk prediction and tailored therapies.
✕Less likely to help
Patients without CeD or IBD or those not yet suited for personalized treatment approaches may see limited direct benefit.
What this research studies
This project looks at how specific genetic differences influence DNA methylation patterns in intestinal and immune cells to identify regulatory changes that drive celiac disease and IBD. By focusing on post-GWAS signals and allele-specific methylation, researchers hope to find markers that predict disease risk, severity, and treatment response. The study collaborates with well-known clinical partners to connect molecular findings with real patient care, with data and samples from human tissues and clinical information. This work could pave the way for more precise diagnoses and personalized treatment plans for people living with CeD and IBD.
Why it matters
Potential benefit: If successful, patients could receive more accurate risk stratification and personalized therapies based on their genetic and epigenetic profiles.
How similar studies have gone: Prior work on post-GWAS analyses and ASM has shown promise in linking regulatory variants to disease, but clinical translation remains ongoing.
Where this research is happening
-
Hackensack University Medical Center
Hackensack, United States Active
Researchers
- Principal investigator: Tycko, Benjamin — Hackensack University Medical Center
- Study coordinator: Tycko, Benjamin
Related research
Other NIH-funded projects on the same topics.
-
Comparative care for IBD in Hispanic patients
A Mayo Clinic Arizona team will study how Crohn’s disease and ulcerative colitis progress and respond to treatments in Hispanic patients using real-world data.
-
Understanding why some people with inflammatory bowel disease fail therapy
A physician-scientist at UNC is pursuing why inflammatory bowel disease treatment stops working so therapies can be kept effective longer.
-
How genes and DNA changes influence celiac disease and inflammatory bowel disease
This project looks for DNA changes that alter gene activity to help predict risk, severity, and treatment response for people with celiac disease and inflammatory bowel disease.
-
Understanding what triggers inflammation in inflammatory bowel diseases
This study is looking at what causes inflammation in people with Crohn's disease and ulcerative colitis who are feeling really well, to help find ways to keep them healthy and prevent flare-ups in the future.
-
Finding ways to block bacterial enzymes that worsen inflammatory bowel diseases
This project looks for new ways to treat inflammatory bowel diseases like Crohn's and ulcerative colitis by targeting specific enzymes made by gut bacteria.
-
Using nanoparticles to deliver epigenetic treatments for inflammatory bowel diseases
This study is exploring a new way to treat inflammatory bowel diseases like ulcerative colitis and Crohn's disease by using tiny particles to deliver special medicines that can help reduce inflammation in your colon, aiming for a treatment that works better and has fewer side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.